Scottsdale, Arizona 85259

  • Parkinson's Disease (PD)


This is a 105-week open-label study to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release formulation of amantadine, in Parkinson's Disease (PD) patients with Levodopa Induced Dyskinesia (LID).


Inclusion Criteria: - Signed a current IRB/REB/IEC-approved informed consent form - Completed all study visits in previous Adamas efficacy study or were ineligible for participation in previous Adamas studies due to having undergone prior deep brain stimulation. - Parkinson's disease, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria - On a stable regimen of antiparkinson's medications at least 30 days prior to screening, including a levodopa preparation administered not less than three times daily. - History of peak dose dyskinesia that might benefit from specific dyskinesia treatment in the judgment of the subject and clinical investigator Exclusion Criteria: - Discontinued ADS-5102 in previous Adamas efficacy study due to intolerable or unacceptable AEs considered to be related to ADS-5102 - History of neurosurgical intervention related to Parkinson's disease, with the exception of deep brain stimulation - History of seizures since completion of participation in previous Adamas studies or within 2 years - History of stroke or TIA since completion of participation in previous Adamas studies or within 2 years - History of cancer since completion of participation in previous Adamas studies or within 2 years, with the following exceptions: adequately treated non-melanomatous skin cancers, localized bladder cancer, non-metastatic prostate cancer or in situ cervical cancer - Presence of cognitive impairment, as evidenced by a Mini-Mental Status Examination (MMSE) score of less than 24 during screening - If female is pregnant or lactating - If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize an effective method of contraception from screening through at least 4 weeks after the completion of study treatment. - Treatment with an investigational drug (other than ADS-5102) or device within 30 days prior to screening - Treatment with an investigational biologic within 6 months prior to screening - Current or planned participation in another interventional clinical trial

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Open-Label Safety Study of ADS-5102 in PD Patients With LID

Official Title:

Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)

Overall Status:

Active, not recruiting

Study Phase:

Phase 3



Minimum Age:

30 Years

Maximum Age:

85 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Adamas Pharmaceuticals, Inc.

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Clinical Trials Director
Study Director
Adamas Pharmaceuticals, Inc.

Study Dates

Start Date:July 2014
Completion Date:March 2018
Completion Type:Anticipated
Primary Completion Date:March 2018
Primary Completion Type:Anticipated
Verification Date:October 2017
Last Changed Date:October 6, 2017
First Received Date:July 25, 2014

Study Outcomes

Outcome Type:Primary Outcome
Measure:Safety and tolerability of ADS-5102 assessed by adverse events, safety-related study drug discontinuation, vital signs, and safety laboratory tests
Time Frame:Up to 105 weeks
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Time Frame:Up to 105 weeks
Safety Issues:False

Study Interventions

Intervention Type:Drug
Arm Name:ADS-5102
Other Name:amantadine HCl extended release

Study Arms

Study Arm Type:Experimental
Arm Name:ADS-5102
Description:amantadine HCl extended release

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Adamas Pharmaceuticals, Inc.

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source:

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.